Bernstein lowered the firm’s price target on Bristol Myers (BMY) to $58 from $62 and keeps a Market Perform rating on the shares post the Q2 report. The firm cites the slow Cobenfy launch and uncertainty on the future expansions for the target cut. It sees the ADEPT2 trial readout as a key catalyst for the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Balanced Outlook on Bristol-Myers Squibb: Strong Earnings Amid Strategic Uncertainties
- Bristol-Myers Squibb’s Earnings Call Highlights Growth and Challenges
- Bristol-Myers Squibb’s Phase 3 Study on KarXT: A Potential Game-Changer for Bipolar-I Disorder
- Bristol-Myers Squibb’s New Study on Deucravacitinib: Market Implications
- Bristol-Myers Squibb’s New Study on Advanced Tumor Treatment: Key Insights for Investors